Glibenclamide And Metformin Oral Tablets (Immediate-Release) Suppliers & Bulk Manufacturers

Available Forms: Tablets IR

Available Strengths: Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg

Reference Brands: Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US)

Category: Diabetes

Glibenclamide and Metformin Oral Tablets (Immediate-Release) is available in Tablets IR and strengths such as Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Glibenclamide and Metformin Oral Tablets (Immediate-Release) is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Glibenclamide and Metformin Oral Tablets (Immediate-Release) can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Glibenclamide (Glyburide) + Metformin tablets are approved in several EU countries under fixed-dose combinations and were previously marketed in the USA as Glucovance®. However, due to evolving safety guidelines—especially related to hypoglycemia risk—its availability may vary. In the EU, these combinations are still prescribed under close monitoring for type 2 diabetes management. The European Medicines Agency (EMA) requires risk-benefit evaluation and labeling for renal monitoring. The U.S. FDA formerly approved Glucovance® under NDA 021178. Healthcare buyers and distributors can find these formulations via Pharmatradz.com for compliant global sourcing.